Summary Adjuvants enhance antibody response against vaccination. We compared the ability of MF59TM-adjuvanted and non-adjuvanted subunit influenza vaccines, containing A/Wyoming/3/03(H3N2), to confer cross-protection against four consecutive drifted strains in the elderly. Neutralizing and haemagglutination-inhibiting antibody were measured. MF59TMadjuvanted vaccine induced a stronger booster response against A/Panama/2007/99(H3N2) than non-adjuvanted vaccine. A/Panama/2007/99(H3N2) circulated widely during the previous 5 years and was included in vaccines over four consecutive seasons. Broader serological protection against drifted strains that circulated 1 and 2 years after vaccination with A/Wyoming/3/03(H3N2) was observed with MF59TM-adjuvanted vaccine. Thus, MF59TMadjuvanted vaccine confers greater immunogenicity than non-adjuvanted vaccines in vulnerable populations.
Ansaldi, F., Bacilieri, S., Durando, P., Sticchi, L., Valle, L., Montomoli, E., et al. (2008). Cross-protection by MF59trade mark-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. VACCINE, 26(12), 1525-1529 [10.1016/j.vaccine.2008.01.019].
Cross-protection by MF59trade mark-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses
MONTOMOLI, E.;
2008-01-01
Abstract
Summary Adjuvants enhance antibody response against vaccination. We compared the ability of MF59TM-adjuvanted and non-adjuvanted subunit influenza vaccines, containing A/Wyoming/3/03(H3N2), to confer cross-protection against four consecutive drifted strains in the elderly. Neutralizing and haemagglutination-inhibiting antibody were measured. MF59TMadjuvanted vaccine induced a stronger booster response against A/Panama/2007/99(H3N2) than non-adjuvanted vaccine. A/Panama/2007/99(H3N2) circulated widely during the previous 5 years and was included in vaccines over four consecutive seasons. Broader serological protection against drifted strains that circulated 1 and 2 years after vaccination with A/Wyoming/3/03(H3N2) was observed with MF59TM-adjuvanted vaccine. Thus, MF59TMadjuvanted vaccine confers greater immunogenicity than non-adjuvanted vaccines in vulnerable populations.
| File | Dimensione | Formato | |
|---|---|---|---|
|
011-2008_Vacc-Ansaldi.pdf
non disponibili
Tipologia:
Post-print
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
345.72 kB
Formato
Adobe PDF
|
345.72 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/42638
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo